• Halozyme entered a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using ENHANZE technology.
• Work targets mutant calreticulin-expressing myeloproliferative neoplasms, aiming for more convenient dosing and delivery versus current development plans.
• Terms include an upfront payment, milestone payments, royalties on net sales, and an option for Incyte to add up to two more targets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607200800PR_NEWS_USPR_____LA07615) on July 20, 2026, and is solely responsible for the information contained therein.